The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.
Elias Kouchakji, MD
Advertisement
Articles by Elias Kouchakji, MD
The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why the representation of non-ambulatory patient populations is necessary in DMD trials.
The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why turning Duchenne muscular dystrophy into a chronic disease rather than a fatal one, is a top priority.
Advertisement
Latest Updated Articles
Elias Kouchakji, MD: Importance of Non-Ambulatory Patients in DMD TrialsPublished: October 16th 2020 | Updated:
Elias Kouchakji, MD: Greatest Unmet Need in Duchenne Muscular DystrophyPublished: October 14th 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
2
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
3
Enhancing Stroke Systems of Care
4
NeurologyLive® Brain Games: October 26, 2025
5
